Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
TipRanksApr 8 22:30 ET
MannKind Announced That It Has Repaid In Full All Outstanding Indebtedness Under Both Its Credit And Security Agreement With Midcap Financial Trust And Its Convertible Promissory Note Issued To Mann Group LLC
Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common st
BenzingaApr 3 06:06 ET
Press Release: MannKind Repays Certain Debt Obligations
MannKind Repays Certain Debt Obligations -- Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 million -- Convertible note issued to Mann Gro
Dow JonesApr 3 06:00 ET
MannKind Corporation (NASDAQ:MNKD) Down to US$1.2b Market Cap, but Institutional Owners May Not Be as Affected After a Year of 9.7% Returns
Yahoo FinanceApr 1 10:30 ET
MannKind Corporation (NASDAQ:MNKD) Is About To Turn The Corner
MannKind Corporation (NASDAQ:MNKD) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. MannKind Corporation, a biopharmaceutical company,
Simply Wall StMar 29 15:30 ET
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
Yahoo FinanceMar 29 11:30 ET
MannKind Corp Announces CFO Transition and New Compensation Plan
TipRanksMar 26 16:23 ET
MannKind CFO Steven Binder to Retire
Seeking AlphaMar 26 16:13 ET
Express News | MannKind Appoints Christopher Prentiss As CFO Effective April 22, 2024; Succeeds Steven Binder
Moomoo 24/7Mar 26 16:07 ET
MannKind: Christopher Prentiss Appointed Chief Fincl Officer, Effective April 22 >MNKD
MannKind: Christopher Prentiss Appointed Chief Fincl Officer, Effective April 22 >MNKD
Dow JonesMar 26 16:07 ET
MannKind: Steven Binder Announces Planned Retirement and Is Appointed Executive Vice Pres, Special Projects, Effective April 22 Through Dec 31 >MNKD
MannKind: Steven Binder Announces Planned Retirement and Is Appointed Executive Vice Pres, Special Projects, Effective April 22 Through Dec 31 >MNKD
Dow JonesMar 26 16:07 ET
Press Release: MannKind Announces CFO Transition
MannKind Announces CFO Transition -- Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through Decemb
Dow JonesMar 26 16:05 ET
MannKind Announces CFO Transition
Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through December 31, 2024 Christopher Prentiss appointed Chief Fina
MannkindMar 26 00:00 ET
MannKind Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 45.74% Cantor Fitzgerald → $6.5 Reiterates Overweight → Overweight 02/28/2024 45.74% Cantor Fit
BenzingaMar 15 10:50 ET
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.
BenzingaMar 11 10:37 ET
What's Going On With MannKind Stock?
MannKind Corporation (NASDAQ:MNKD) shares are trending on social media Monday. Here's a look at what's going on.What To Know:The company announced initial meal challenge data from INHALE-3, a Phase 4
BenzingaMar 11 10:28 ET
INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
Post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps Subjects utilizing inhaled insulin experienced a
MannkindMar 11 00:00 ET
Cramer Says Sprout Social Is In A 'Hot Spot,' But This Energy Stock Is 'Too Down And Out'
On CNBC's "Mad Money Lightning Round," Jim Cramer said he needs to do more work on Sprout Social, Inc. (NASDAQ:SPT) as it is in a "hot spot, but the stock is not making money.
BenzingaMar 8 09:13 ET
Express News | MannKind Announced That New Clinical Data From INHALE-3 Phase 4 Study Of Inhaled Insulin (Plus Basal) Vs. Standard Of Care At The International Conference On Advanced Technologies And Treatments For Diabetes
Moomoo 24/7Mar 5 06:08 ET
MannKind Announces New Clinical Data From Inhale-3 Study to Be Presented by Dr. Irl B. Hirsch at ATTD on March 8
Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza (insulin human) Inhalation Powder)DANBURY, Conn. and WESTL
MannkindMar 5 00:00 ET
No Data
No Data